Status:
UNKNOWN
Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial
Lead Sponsor:
Mazandaran University of Medical Sciences
Conditions:
Coronavirus Infections
Eligibility:
All Genders
30-70 years
Phase:
NA
Brief Summary
Coronavirus disease 2019 (COVID-19) was recognized as a pandemic on March 11, 2020 by the World Health Organization. The virus that causes COVID-19 (SARS-CoV-2) is easily transmitted through person to...
Eligibility Criteria
Inclusion
- Recipient:
- COVID-19 Patients
- Consent to attend the study
- Age 30 to 70 years
- Don't be intubated
- PaO2 / FiO2 is above 200 or Spo2 is greater than 85%.
- Donator:
- Complete recovery from severe COVID-19 disease and hospital discharge
- Consent to donate blood to the infected person
- Age 30 to 60 years
- Has normal CBC test results
- Negative COVID-19 RT-PCR test
Exclusion
- Recipient:
- A history of hypersensitivity to blood transfusions or its products
- History of IgA deficiency
- Heart failure or any other factor that prevents the transmission of of 500 ml plasma
- Entering the intubation stage
- Donator:
- Patients infected with blood-borne viral / infectious diseases
- Underlying heart disease, low or high blood pressure, diabetes, epilepsy, and anything that may prohibit blood donation.
- Use of banned drugs for blood donation (eg, ethertinate, acitretin, aliotretinoin, isotretinoin, antiandrogens, NSAIDs, etc.)
- Use of different drugs
- Other prohibited donations based on blood transfusion standards
Key Trial Info
Start Date :
March 28 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2020
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04327349
Start Date
March 28 2020
End Date
September 30 2020
Last Update
March 31 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Imam Khomeini Hospital, Mazandaran University of Medical Sciences
Sari, Mazandaran, Iran, 4816633131